US HB6925 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on May 19 2020 - 25% progression, died in committee
Action: 2020-05-19 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on May 19 2020 - 25% progression, died in committee
Action: 2020-05-19 - Referred to the House Committee on Energy and Commerce.
Pending: House Energy And Commerce Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Exempts non-invasive diagnostic devices from the regulatory authority of the Food and Drug Administration. The bill defines non-invasive diagnostic device as one that does not penetrate the skin or any other membrane of the body, is not inserted or implanted into the body, causes no more than ephemeral compression or temperature changes to in situ bodily tissues, and does not subject bodily tissues to ionizing radiation.
Title
Medical Innovation Acceleration Act of 2020
Sponsors
| Rep. Andy Biggs [R-AZ] |
History
| Date | Chamber | Action |
|---|---|---|
| 2020-05-19 | House | Referred to the House Committee on Energy and Commerce. |
| 2020-05-19 | House | Introduced in House |
Subjects
Administrative remedies
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Health
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Health
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/116th-congress/house-bill/6925/all-info |
| Text | https://www.congress.gov/116/bills/hr6925/BILLS-116hr6925ih.pdf |
